MRSN
NASDAQ
US
Mersana Therapeutics, Inc. - Common Stock
$29.08
+0.0 (+0.0%)
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$144.6M
ROE
-401.4%
Margin
-211.2%
D/E
2426.79
Beta
0.43
52W
$5–$41
Wall Street Consensus
14 analysts · Apr 20262
Strong Buy
4
Buy
8
Hold
0
Sell
0
Strong Sell
42.9%
Buy Rating
Price Chart
Similar Stocks
IMUX
Immunic Inc
$64.2M
TNYA
Tenaya Therapeutics Inc
$154.0M
HRTX
Heron Therapeutics Inc
$238.4M
UNCY
Unicycive Therapeutics Inc
$124.0M
DTIL
Precision BioSciences Inc
$100.1M
FATE
Fate Therapeutics Inc
$113.3M
SPRO
Spero Therapeutics Inc
$131.3M
CBUS
Cibus Inc
$94.5M
BDTX
Black Diamond Therapeutics Inc
P/E 6.4
$138.4M
KLRS
Kalaris Therapeutics Inc
$141.3M
Earnings
Beat rate: 75.0%
Next Report
May 13, 2026
EPS Estimate: $-3.41
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-3.41 | — | — |
| Sep 2025 | $-1.64 | $-1.51 | +$0.13 |
| Jun 2025 | $-4.01 | $-4.87 | $-0.86 |
| Mar 2025 | $-4.95 | $-4.75 | +$0.20 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -401.4% | -401.4% | -401.4% | -401.4% | -401.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -795.0% | -212.9% | -212.9% | -212.9% | -211.2% | -211.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | — | 2426.79 | 2426.79 | 2426.79 | 2426.79 | 2426.79 |
| Current Ratio | 1.35 | 1.35 | 1.35 | 1.35 | 1.39 | 1.39 |
Key Ratios
ROA (TTM)
-69.3%
P/S (TTM)
4.36
P/B
7.6
EPS (TTM)
$-14.08
CF/Share
$-1.76
Rev Growth 3Y
+904.1%
52W High
$40.88
52W Low
$5.21
$5.21
52-Week Range
$40.88
How does MRSN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
MRSN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
4.4
▼
66%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
7.6
▲
208%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
MRSN profitability vs Biotechnology peers
ROE
-401.4%
▼
496%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-211.2%
▲
26%
above
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-69.3%
▼
48%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
MRSN financial health vs Biotechnology peers
D/E ratio
2426.8
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.4
▼
69%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.4
▼
56%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
MRSN fundamentals radar
MRSN
Peer median
Industry
MRSN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
MRSN vs peers: key metrics
Latest News
No related news yet